98%
921
2 minutes
20
Keratoconus, a disorder characterized by corneal thinning and weakening, results in vision loss. Corneal crosslinking (CXL) can halt the progression of keratoconus. The development of accelerated corneal crosslinking (A-CXL) protocols to shorten the treatment time has been hampered by the rapid depletion of stromal oxygen when higher UVA intensities are used, resulting in a reduced cross-linking effect. It is therefore imperative to develop better methods to increase the oxygen concentration within the corneal stroma during the A-CXL process. Photocatalytic oxygen-generating nanomaterials are promising candidates to solve the hypoxia problem during A-CXL. Biocompatible graphitic carbon nitride (g-CN) quantum dots (QDs)-based oxygen self-sufficient platforms including g-CN QDs and riboflavin/g-CN QDs composites (RF@g-CN QDs) have been developed in this study. Both display excellent photocatalytic oxygen generation ability, high reactive oxygen species (ROS) yield, and excellent biosafety. More importantly, the A-CXL effect of the g-CN QDs or RF@g-CN QDs composite on male New Zealand white rabbits is better than that of the riboflavin 5'-phosphate sodium (RF) A-CXL protocol under the same conditions, indicating excellent strengthening of the cornea after A-CXL treatments. These lead us to suggest the potential application of g-CN QDs in A-CXL for corneal ectasias and other corneal diseases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11217369 | PMC |
http://dx.doi.org/10.1038/s41467-024-49645-8 | DOI Listing |
Ophthalmologie
September 2025
Klinik für Augenheilkunde am Universitätsklinikum der Medizinischen Hochschule Brandenburg, Hochstr. 29, 14770, Brandenburg, Deutschland.
Keratectasias including keratoconus are pathological curvature anomalies of the human cornea, which can progress and lead to permanent visual impairment. Corneal crosslinking can be used to stabilize the disease. Criteria for performing crosslinking have been defined by legislation in Germany, including an increase of the maximum anterior surface curvature Kmax by ≥ 1 diopter within 12 months.
View Article and Find Full Text PDFJ Refract Surg
September 2025
From the Department of Ophthalmology at University of São Paulo, São Paulo, Brazil.
Purpose: To analyze stabilization results using various standard and accelerated corneal cross-linking (CXL) protocols in patients younger than 18 years.
Methods: This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines. A bibliographic search was carried out based on PubMed and Scopus data, with the last being performed in December 2024.
Clin Exp Ophthalmol
September 2025
Health New Zealand Tairawhiti, Gisborne, New Zealand.
Background: The prevalence of keratoconus in New Zealand is higher compared to the global prevalence of 1.38 per 1000, with Māori and Pacific Islander being over-represented. The form of keratoconus in New Zealand has been shown to have a more rapid progression of disease.
View Article and Find Full Text PDFACS Appl Mater Interfaces
September 2025
Department of Ophthalmology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, 321 Zhongshan Road, Nanjing 210008, China.
Pterygium is a common ocular surface lesion, and postoperative recurrence remains a major challenge due to insufficient therapeutic strategies targeting fibroblast proliferation and inflammation. Fibrinogen hydrogel (Fibrin glue, FG), a bioadhesive hydrogel, is widely used in pterygium surgery to secure conjunctival autografts. However, its low adhesion often leads to graft detachment, hindering effective repair.
View Article and Find Full Text PDFCureus
August 2025
Ophthalmology, Huffman and Huffman Eye Physicians and Surgeons, London, USA.
Purpose: This retrospective crossover study compares two-month outcomes of cyclosporine A ophthalmic emulsion 0.05% (Restasis) versus cross-linked hyaluronic acid gel (Lacrifill), a novel canalicular occlusive device, in 20 patients with refractory aqueous-deficient dry eye disease (DED) at a rural optometry clinic.
Methods: In patients with moderate to severe DED, two-month outcomes for Restasis and Lacrifill (after a washout period) were compared using tear breakup time (TBUT), Schirmer scores, corneal staining (Efron scale), and Ocular Surface Disease Index (OSDI) scores.